| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000032998 |
| Receipt No. | R000037577 |
| Official scientific title of the study | Effect of a Food to Suppress the Increase in Postprandial Triglyceride Levels |
| Date of disclosure of the study information | 2018/06/20 |
| Last modified on | 2018/12/04 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | Effect of a Food to Suppress the Increase in Postprandial Triglyceride Levels | |
| Title of the study (Brief title) | Effect of a Food to Suppress the Increase in Postprandial Triglyceride Levels | |
| Region |
|
|
| Condition | ||
| Condition | N/A (healthy adults) | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | This study aims to examine effect of a food to suppress the increase in postprandial triglyceride level. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | [1]Efficacy evaluation (changes, increase and decrease of TG, NEFA, lipoprotein fraction, RLP-C [before ingestion of a challenge diet, and 2, 3, 4, 6 hours after ingestion of a challenge diet; AUC and iAUC of TG, NEFA, lipoprotein fraction, RLP-C [observation period I and II]). |
| Key secondary outcomes | *Indexes for safety
[1]Blood pressure, pulsation (screening and before ingestion of a challenge diet). [2]Weight, body fat percentage, BMI (screening and before ingestion of a challenge diet) . [3]Doctor's questions (screening, before ingestion of a challenge diet, and 6 hours after ingestion of a challenge diet). [4]Subject's diary (from one day before ingestion of a challenge diet in observation period I to one day before ingestion of a challenge diet in observation period II) *Other indexes [1]Hematologic test (screening) [2]Blood biochemical test (screening) [3]Urine analysis (screening) |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Cross-over |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -no one is blinded |
| Control | No treatment |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | [1]Oral ingestion of a test food (1 time).
[2]Oral ingestion of a challenge diet. [3]Observation. [4]Washout (over 6 days) [5]No ingestion of a test food. [6]Oral ingestion of a challenge diet. [7]Observation. |
|
| Interventions/Control_2 | [1]No ingestion of a test food.
[2]Oral ingestion of a challenge diet. [3]Observation. [4]Washout (over 6 days) [5]Oral ingestion of a test food (1 time). [6]Oral ingestion of a challenge diet. [7]Observation. |
|
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | [1]Japanese males and females aged 20-65 years.
[2]Individuals who are healthy and are not suffered from a chronic malady including skin disease. [3]Individuals whose triglyceride level is normal or who are mild hyperlipemia (120mg/dL-199mg/dL). [4]Individuals whose written informed consent has been obtained. [5]Individuals who can visit an inspection facility and be inspected in designated days. [6]Individuals judged appropriate for the study by the principal. |
|||
| Key exclusion criteria | [1]Individuals using medical products.
[2]Individuals who are or are under treatment or have a history of hyperlipidemia, hypertension, diabetes, mental disabilities, sleep disorder or the other serious dysfunctions. [3]Individuals who used a drug to treat in the past 1 month (One-shot medicine of a headache, menstrual pain and a cold removes it). [4]Individuals who have a history of serious hepatopathy, kidney damage, heart disease, lung disease, or blood disease. [5]Individuals who have digestive organ disease (disease of an appendix is removed). [6]Individuals whose menstrual period is during the test period and with serious anemia or poor physical condition during the period (only for females). [7]Individuals whose BMI is over 30kg/m2. [8]Individuals who donated blood over 200mL in the past 1 month or over 400mL in the past 3 months. [9]Individuals with serious anemia. [10]Individuals who are sensitive to test products or causes severe allergy in a food and medical supplies. [11]Individuals who cannot intake every loading food or test food. [12]Individuals who are or are possibly pregnant, or are lactating. [13]Individuals who are based on average alcohol per 1 day and exceeds 60g/day. [14]Individuals whose life style will change during the test period (ex. travel for a long time). [15Individuals who had a habit to ingest health-promoting foods, foods for specified health uses, health foods, or supplements which adopt to improve lipid metabolism or glucose metabolism in the past 3 months or will ingest those foods during the test period. [16]Individuals who participated in other clinical studies in the past 3 months. [17]Individuals judged inappropriate for the study by the principal. |
|||
| Target sample size | 40 | |||
| Research contact person | |
| Name of lead principal investigator | Ryuzo Hanada |
| Organization | Medical Corporation SOUSEIKAI Sumida Hospital |
| Division name | Internal Medicine |
| Address | Random Square Honjo, 1-29-1 Honjo Sumida-ku Tokyo, 130-0004 JAPAN |
| TEL | 03-5608-7276 |
| info@tes-h.co.jp | |
| Public contact | |
| Name of contact person | Ryoma Shimizu |
| Organization | TES Holdings Co., Ltd |
| Division name | Administrative Department of Clinical Trials |
| Address | 6F University of Tokyo Entrepreneur Plaza 7-3-1 Hongo Bunkyo-ku Tokyo 113-0033, JAPAN |
| TEL | +81-3-6801-8480 |
| Homepage URL | |
| r.shimizu@tes-h.co.jp | |
| Sponsor | |
| Institute | TES Holdings Co., Ltd |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Riken Vitamin Co., Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000037577 |